Advertisement

Topics

Taking lenient stance, NICE backs neuroblastoma drug

08:42 EDT 12 Jul 2018 | pharmaphorum

NICE has recommended EUSA Pharma’s neuroblastoma treatment Qarziba (dinutuximab beta) in final draft guidance after taking a lenient stance because of the rare nature of the disease, and after the manufacturer agreed to cut its price. The drug is ...

Original Article: Taking lenient stance, NICE backs neuroblastoma drug

NEXT ARTICLE

More From BioPortfolio on "Taking lenient stance, NICE backs neuroblastoma drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...